Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 177 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma MOST POPULAR ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) February 7, 2019 Hopes for the future of cancer research – a video from... April 16, 2023 FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications December 10, 2021 Oncolytic Virus Enables the Immune System to Attack Tumors October 12, 2023 Load more HOT NEWS Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... Cancer Moonshot℠ Workshop Highlights Recent Research Advances NCI-MATCH Update: More Labs, New Arms, and Initial Findings EMA Recommends Extension of Indications for Niraparib
